



**Memo No.** 2022-035  
**Date:** 19-Sep-2022  
**Memo To:** Clients  
**Re:** *Various*

---

### **Service Updates**

Effective October 3<sup>rd</sup>, 2022, the methodology of ***Amiodarone and Metabolite, Serum*** at University Health Network will be revised from HPLC to LC-MS/MS. The new method is robust and free of interference. Due to this change, serum amiodarone and metabolite values are expected to increase by a mean of 0.1 -0.2 mg/L.

Effective 3-Oct-2022: **[Amiodarone and Metabolite, Serum](#)**

HL7 interface codes are unchanged.

**[Histone Group Antibodies, Serum/Plasma](#)** at London Health Sciences Center will not be available effective October 11, 2022. The orders received at ICL after October 7<sup>th</sup>, 2022, will be sent to our new routine service at Quest Diagnostics. Information for the Quest service will be available soon.

---

### **ICL Online Test Catalogue Update**

The listing for **[Carcinoembryonic Antigen \(CEA\), Serum](#)** at Sunnybrook Hospital was updated to include frozen stability: Refrigerated 7 days, Frozen 6 months.

---

### **New test**

**[IGF-1 LC/MS with Z-Score, Serum](#)** (Quest Diagnostics)

Please refer to the online Test Catalogue for details.

---

If you have further questions, please contact Client Care at (416) 422-3000 Ext. 300 or [info@ICLabs.ca](mailto:info@ICLabs.ca)

Dr. Shashank Tilak, Ph.D., DCC  
Laboratory Director  
(416) 422-3000 Ext. 221  
[ShashTilak@ICLabs.ca](mailto:ShashTilak@ICLabs.ca)

**Want to receive updates by e-mail? Please contact Client Care [info@ICLabs.ca](mailto:info@ICLabs.ca)**